Study results in a rare form of obesity could help the company expand use of Imcivree, which is approved for two genetically driven forms of excess weight.

To what extent will health clinics go to keep selling in-demand weight-loss drugs now that the FDA has outlawed cheaper ...

Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.

Ford’s first quarter sales were off 1.3% compared to a year earlier, largely due to the discontinuation last year of its Ford ...

Novo Nordisk has signed a deal worth up to $1bn with Lexicon Pharmaceuticals for the exclusive global rights to LX9851, an ...

Bank of America analysts on Friday said Novo Nordisk may miss first-quarter expectations, as sales of its blockbuster Wegovy ...

Novo Nordisk said Thursday that the rampant growth of the U.S.’ compounded drug industry was hurting Wegovy sales, and warned ...

Eli Lilly (NYSE: LLY) has emerged as one of the hottest stocks in the GLP-1 realm -- underscored by its combination of ...

Novo Nordisk has acquired the global rights to United Laboratories’ triple-agonist weight-loss and diabetes drug in a deal ...

In the third quarter, Novo Nordisk reported Wegovy sales grew 79% to almost $2.5 billion, while Lilly booked $1.26 billion from Zepbound, around $500 million lower than analyst forecasts.

Novo Nordisk’s Wegovy (semaglutide) and Eli Lilly’s Zepbound (tirzepatide) currently lead the market, driving strong sales growth ... with GlobalData forecasting a 0.7% annual increase ...

Eli Lilly has revised its revenue forecast for 2024 after seeing ... and operational performance," continued Ricks. "Sales of Mounjaro and Zepbound posted robust sales growth in Q4, and we expect ...